blood transfusion News
-
Anxin medicine introduces you to the secrets of medical polymer materials
Medical polymer materials for the first time into the line of sight of people in 1949, is the first published the prospect of medical polymer materials, for the first time introduced the use of poly (methyl methacrylate as a person's skull, joint and femoral, using polyamide as the clinical application of surgical suture, since then, usher in rapid development of medical polymer materials, is ...
-
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
The Companies are collaborating on an orderly transition through first half of 2022 while Sangamo explores options to advance the program, including seeking a new partner Phase 1/2 PRECIZN-1 study of investigational SAR445136 expected to be completed as planned; final patients in study expected to be dosed in third quarter of 2022 Preliminary proof-of-concept data presented at ASH 2021 showed ...
-
Reetoo made a wonderful appearance at CACLP
From March 28 to March 30, 2021, the 18th China International Laboratory Medicine and Blood Transfusion Instruments and Reagent Expo was successfully held at Chongqing International Expo Center. Reetoo Biotech carries 7 major types of specimen series products, including vaginal secretion detector, sperm quality analyzer, automatic chromosome microscopic image scanning system, automatic urine ...
-
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
No adverse events related to investigational SAR445136 were reported All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood transfusions post engraftment Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 ...
-
Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Alydia Health announced today that they have entered into a definitive agreement pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health. Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum ...
-
Agilent Technologies presents 2011 manfred donike award for excellence in sports-doping detection to german and swiss researchers
Agilent Technologies, Inc. (NYSE: A) today announced it has presented the 2011 Manfred Donike Award for scientific excellence in sports-doping testing to Simon Beuck and Nicolas Leuenberger. Agilent sponsors this annual award to recognize distinguished scientific contributions in doping analysis. Award winners are scientists who exemplify the spirit and scientific leadership of doping control ...
-
Fibralign Announces Strategic Partnership with Terumo
Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced today that it has executed a long term distributor agreement with Terumo Corporation to market and distribute the BioBridge® Collagen Matrix in Japan for treating and preventing secondary lymphedema. BioBridge is a sterile implantable biocompatible and biodegradable surgical mesh made of highly ...
-
NIAID awards Phase I contract to Kephera Diagnostics for the development of a new test for Chagas disease
The National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), has awarded a Phase I, $300,000 Small Business Innovative Research (SBIR) contract to Kephera Diagnostics to develop a new test for Chagas disease, the company announced today. The contract, awarded in response to a targeted solicitation from NIAID aimed at improving ...
-
Gauss Raises $20 Million in Series C From Northwell Health Softbank Ventures Korea for AI-Enabled Platform for the Operating Room
Gauss Surgical, an AI-driven healthcare technology company, raised $20 million in Series C funding from Northwell Health and SoftBank Ventures Korea, the global early-stage venture capital arm of SoftBank Group, as well as from the LS Polaris Innovation Fund and seven other leading US health systems. The proceeds of the round will be used to accelerate the adoption of its Triton platform in ...
-
Grifols and Shanghai RAAS close their strategic alliance in China
Grifols controls a 26.20% stake in Shanghai RAAS (economic and voting rights) in exchange for a non-majority share on behalf of Shanghai RAAS (45% economic rights and 40% voting rights) in Grifols’ subsidiary, Grifols Diagnostic Solutions (GDS) Over the past 35 years, Grifols has increasingly expanded its presence in China, which is currently the company’s third-largest sales ...
-
Merck to initiate proof-of-concept study of posaconazole for chronic chagas disease, recognized by WHO as one of the world`s neglected tropical diseases
Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom ...
-
BIOtechNOW featured IVS’s participating BIO Innovation Zone
BIOtechNOW featured IVS’s participating BIO Innovation Zone Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech ...
-
Grifols continues to reinforce its commitment to all stakeholders as a response to COVID-19
Grifols has adopted a number of measures since the onset of the pandemic in order to respond to the needs of its stakeholders. The company continually monitors the progression of COVID-19, analyzing and evaluating its potential impact on its workforce and operations to guarantee minimal delays or interruptions in our operations as Grifols’ products and services are essential for patients ...
-
Abbott receives FDA approval for first fully automated blood test for `kissing bug` disease
Abbott received Biologic License Application (BLA) approval from the United States Food and Drug Administration (FDA) for the ABBOTT PRISM Chagas test. The test is a fully automated blood screening assay that can detect antibodies to Trypansoma cruzi (T. cruzi), a parasite found only in the Americas and most commonly acquired through contact with the blood-sucking triatomine or "kissing bug." ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you